292 related articles for article (PubMed ID: 18798220)
1. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
2. Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells.
Lacreusette A; Barbieux I; Nguyen JM; Pandolfino MC; Dréno B; Jacques Y; Godard A; Blanchard F
J Pathol; 2009 Apr; 217(5):665-76. PubMed ID: 19097071
[TBL] [Abstract][Full Text] [Related]
3. Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions.
Lu C; Rak JW; Kobayashi H; Kerbel RS
Cancer Res; 1993 Jun; 53(12):2708-11. PubMed ID: 8504408
[TBL] [Abstract][Full Text] [Related]
4. Loss of oncostatin M receptor beta in metastatic melanoma cells.
Lacreusette A; Nguyen JM; Pandolfino MC; Khammari A; Dreno B; Jacques Y; Godard A; Blanchard F
Oncogene; 2007 Feb; 26(6):881-92. PubMed ID: 16909117
[TBL] [Abstract][Full Text] [Related]
5. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
6. Tissue prognostic markers for adoptive immunotherapy in melanoma.
Quereux G; Pandolfino MC; Knol AC; Khammari A; Volteau C; Nguyen JM; Dreno B
Eur J Dermatol; 2007; 17(4):295-301. PubMed ID: 17540635
[TBL] [Abstract][Full Text] [Related]
7. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.
Besser MJ; Treves AJ; Itzhaki O; Hardan I; Nagler A; Papa MZ; Catane R; Winkler E; Shalmon-Zifroni B; Schachter J
Isr Med Assoc J; 2006 Mar; 8(3):164-8. PubMed ID: 16599050
[TBL] [Abstract][Full Text] [Related]
9. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
10. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
Wagley Y; Yoo YC; Seo HG; Rhee MH; Kim TH; Kang KW; Nah SY; Oh JW
Biochem Biophys Res Commun; 2007 Mar; 354(4):985-91. PubMed ID: 17274948
[TBL] [Abstract][Full Text] [Related]
11. Development of an effective method for dendritic cell immunotherapy of mouse melanoma.
Lee TH; Cho HK; Cho YH; Lee MG
Scand J Immunol; 2009 Aug; 70(2):85-92. PubMed ID: 19630913
[TBL] [Abstract][Full Text] [Related]
12. Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?
Peuvrel L; Nguyen JM; Khammari A; Quereux G; Brocard A; Dreno B
J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1311-7. PubMed ID: 21348897
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
Silvani A; Ferrari G; Paonessa G; Toniatti C; Parmiani G; Colombo MP
Cancer Res; 1995 May; 55(10):2200-5. PubMed ID: 7743524
[TBL] [Abstract][Full Text] [Related]
14. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
15. The DNA ploidy and proliferative activity of transplantable melanoma cells in regard to their secretory function.
Wachulska M; Kozłowska K; Cichorek M
Neoplasma; 2005; 52(4):280-6. PubMed ID: 16059642
[TBL] [Abstract][Full Text] [Related]
16. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
[TBL] [Abstract][Full Text] [Related]
17. Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
Xu Y; Zhang F; Qin L; Miao J; Sheng W; Xie Y; Xu X; Yang J; Qian H
Melanoma Res; 2014 Feb; 24(1):20-31. PubMed ID: 24300090
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-based therapy for melanoma: pre-clinical studies.
Shurin MR; Kirkwood JM; Esche C
Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
[TBL] [Abstract][Full Text] [Related]
19. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
Marincola FM; Venzon D; White D; Rubin JT; Lotze MT; Simonis TB; Balkissoon J; Rosenberg SA; Parkinson DR
Cancer Res; 1992 Dec; 52(23):6561-6. PubMed ID: 1423301
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
Möller P; Wittig B; Schadendorf D
Anticancer Res; 1998; 18(2B):1237-41. PubMed ID: 9615794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
